Centers For Medicare and Medicaid Services releases 'request for information' on how to approach development of new payment models for prescription drugs in government-sponsored insurance.
The Trump Administration will explore new payment models for prescription drugs at the Center for Medicare and Medicaid Innovation (CMMI) as part of a plan to redirect the focus of the reimbursement laboratory.
The Centers for Medicare and Medicaid Services released a "request for information" Sept. 20 seeking public comments on...
If the UK is to become a top three country in the cell and gene therapy space, it must overcome the current political “stumbling block” around making changes that recognize the value of these therapies, Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, tells the Pink Sheet.
While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
Recommendations from the health technology assessment institute, NICE, reflect a strategic shift from treating type 2 diabetes to proactively preventing future complications of the condition.
Complaint names LillyDirect in action targeting the company’s free nurse and reimbursement support programs for health care providers.
The UK drug regulator has introduced several changes in recent months, such as the introduction of a decentralized manufacturing regulation. Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, explains what these changes mean for the cell and gene industry.
